ATE472604T1 - Verfahren zur herstellung von proteinen - Google Patents
Verfahren zur herstellung von proteinenInfo
- Publication number
- ATE472604T1 ATE472604T1 AT03750495T AT03750495T ATE472604T1 AT E472604 T1 ATE472604 T1 AT E472604T1 AT 03750495 T AT03750495 T AT 03750495T AT 03750495 T AT03750495 T AT 03750495T AT E472604 T1 ATE472604 T1 AT E472604T1
- Authority
- AT
- Austria
- Prior art keywords
- producing proteins
- proteins
- producing
- transient expression
- secreted protein
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000003306 harvesting Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000001938 protoplast Anatomy 0.000 abstract 1
- 230000010474 transient expression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20020020382 EP1398383A1 (de) | 2002-09-12 | 2002-09-12 | Verfahren zur Herstellung von Proteinen |
| EP03015881 | 2003-07-11 | ||
| PCT/EP2003/009959 WO2004024927A1 (en) | 2002-09-12 | 2003-09-08 | Protein production method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE472604T1 true ATE472604T1 (de) | 2010-07-15 |
Family
ID=31995519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03750495T ATE472604T1 (de) | 2002-09-12 | 2003-09-08 | Verfahren zur herstellung von proteinen |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1539966B1 (de) |
| AT (1) | ATE472604T1 (de) |
| AU (1) | AU2003270152A1 (de) |
| DE (1) | DE60333201D1 (de) |
| DK (1) | DK1539966T3 (de) |
| ES (1) | ES2347325T3 (de) |
| PT (1) | PT1539966E (de) |
| SI (1) | SI1539966T1 (de) |
| WO (1) | WO2004024927A1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0416262B1 (pt) | 2003-11-05 | 2022-04-12 | Roche Glycart Ag | Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica |
| PT1871805T (pt) | 2005-02-07 | 2019-12-02 | Roche Glycart Ag | Moléculas de ligação a antigénios que se ligam ao rfce, vetores que as codificam e as suas utilizações |
| KR101460932B1 (ko) | 2005-08-26 | 2014-11-12 | 로슈 글리카트 아게 | 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자 |
| SE529610C2 (sv) | 2006-02-13 | 2007-10-02 | Alfa Laval Corp Ab | Centrifugalseparator |
| AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
| KR101528013B1 (ko) | 2009-08-31 | 2015-06-16 | 로슈 글리카트 아게 | 친화성-성숙된 인간화된 항-ｃｅａ 단일클론 항체 |
| WO2011101328A2 (en) | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
| US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
| RU2584597C2 (ru) | 2010-08-13 | 2016-05-20 | Рош Гликарт Аг | Антитела против а2 тенасцина с и способы их применения |
| ES2655616T3 (es) | 2010-08-13 | 2018-02-20 | Roche Glycart Ag | Anticuerpos anti-FAP y procedimientos de uso |
| EP2672999A2 (de) | 2011-02-10 | 2013-12-18 | Roche Glycart AG | Verbesserte immuntherapie |
| CA2827170A1 (en) | 2011-02-11 | 2012-08-16 | David M. Hilbert | Monovalent and multivalent multispecific complexes and uses thereof |
| HUE036229T2 (hu) | 2011-03-02 | 2018-06-28 | Roche Glycart Ag | CEA antitestek |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| PL2748202T3 (pl) | 2011-08-23 | 2018-12-31 | Roche Glycart Ag | Dwuswoiste cząsteczki wiążące antygen |
| CN103890006A (zh) | 2011-08-23 | 2014-06-25 | 罗切格利卡特公司 | 抗mcsp抗体 |
| PL3434695T3 (pl) | 2012-08-07 | 2021-05-17 | Roche Glycart Ag | Ulepszona immunoterapia |
| US20140242083A1 (en) | 2013-02-26 | 2014-08-28 | Roche Glycart Ag | Anti-mcsp antibodies |
| KR102788389B1 (ko) | 2015-04-06 | 2025-03-31 | 서브도메인, 엘엘씨 | 드 노보 결합 도메인 함유 폴리펩티드 및 그의 용도 |
| CA2999917A1 (en) | 2015-09-24 | 2017-03-30 | Abvitro Llc | Hiv antibody compositions and methods of use |
| KR102850929B1 (ko) | 2015-12-09 | 2025-08-27 | 에프. 호프만-라 로슈 아게 | 항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체 |
| EP3178848A1 (de) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente |
| CN108699155B (zh) | 2016-03-01 | 2023-03-21 | 豪夫迈·罗氏有限公司 | 具有改变的细胞死亡诱导的奥滨尤妥珠单抗变体 |
| JP7089483B2 (ja) | 2016-05-11 | 2022-06-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 修飾された抗テネイシン抗体及び使用方法 |
| EP3252078A1 (de) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs |
| CN110603266A (zh) | 2016-06-02 | 2019-12-20 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体 |
| KR102769634B1 (ko) | 2017-04-27 | 2025-02-19 | 테사로, 인코포레이티드 | 림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도 |
| JP7285267B2 (ja) | 2017-11-14 | 2023-06-01 | アーセルクス インコーポレイテッド | Ｄドメイン含有ポリペプチドおよびその使用 |
| IL314701A (en) | 2017-11-14 | 2024-10-01 | Arcellx Inc | Multifunctional immune cell therapies |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US20210221908A1 (en) | 2018-06-03 | 2021-07-22 | Lamkap Bio Beta Ltd. | Bispecific antibodies against ceacam5 and cd47 |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN109234284B (zh) * | 2018-09-14 | 2021-04-09 | 昆明理工大学 | 一种三七类甜蛋白基因PnTLP5及应用 |
| CN109295068B (zh) * | 2018-09-14 | 2021-04-09 | 昆明理工大学 | 一种三七类甜蛋白基因PnTLP2及应用 |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| EP3831849A1 (de) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispezifische antikörper gegen ceacam5 und cd47 |
| JP2023509708A (ja) | 2020-01-03 | 2023-03-09 | マレンゴ・セラピューティクス，インコーポレーテッド | 抗ｔｃｒ抗体分子およびその使用 |
| EP4228779A1 (de) | 2020-10-13 | 2023-08-23 | Avitide LLC | Aav8-affinitätswirkstoffe |
| WO2022081779A1 (en) | 2020-10-13 | 2022-04-21 | Avitide LLC | Affinity ligand libraries of three-helix bundle proteins and uses thereof |
| WO2022178396A1 (en) | 2021-02-19 | 2022-08-25 | Avitide LLC | Aav2 affinity agents |
| EP4313083A4 (de) | 2021-03-26 | 2025-06-18 | Arcellx, Inc. | Multifunktionelle immunzelltherapien |
| WO2022223651A1 (en) | 2021-04-23 | 2022-10-27 | F. Hoffmann-La Roche Ag | Prevention or mitigation of nk cell engaging agent-related adverse effects |
| US20250059258A1 (en) | 2021-12-24 | 2025-02-20 | Avitide LLC | Ch1 domain affinity ligands and agents |
| WO2024025911A1 (en) | 2022-07-29 | 2024-02-01 | Avitide LLC | An affinity agent comprising a ligand that binds vce and comprises seq id no: 1 |
| AU2023339047A1 (en) | 2022-09-09 | 2025-03-20 | Repligen Corporation | Affinity agents |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19947290A1 (de) * | 1999-10-01 | 2001-04-19 | Greenovation Pflanzenbiotechno | Verfahren zur Herstellung proteinöser Substanzen |
-
2003
- 2003-09-08 ES ES03750495T patent/ES2347325T3/es not_active Expired - Lifetime
- 2003-09-08 AT AT03750495T patent/ATE472604T1/de active
- 2003-09-08 EP EP03750495A patent/EP1539966B1/de not_active Expired - Lifetime
- 2003-09-08 DE DE60333201T patent/DE60333201D1/de not_active Expired - Lifetime
- 2003-09-08 WO PCT/EP2003/009959 patent/WO2004024927A1/en not_active Ceased
- 2003-09-08 DK DK03750495.8T patent/DK1539966T3/da active
- 2003-09-08 PT PT03750495T patent/PT1539966E/pt unknown
- 2003-09-08 AU AU2003270152A patent/AU2003270152A1/en not_active Abandoned
- 2003-09-08 SI SI200331863T patent/SI1539966T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1539966T1 (sl) | 2010-10-29 |
| ES2347325T3 (es) | 2010-10-28 |
| DK1539966T3 (da) | 2010-10-04 |
| WO2004024927A1 (en) | 2004-03-25 |
| DE60333201D1 (de) | 2010-08-12 |
| EP1539966B1 (de) | 2010-06-30 |
| AU2003270152A1 (en) | 2004-04-30 |
| PT1539966E (pt) | 2010-09-14 |
| EP1539966A1 (de) | 2005-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE472604T1 (de) | Verfahren zur herstellung von proteinen | |
| DE60335195D1 (de) | Mutante e. coli-appa-phytaseenzyme und natürliche varianten davon, solche phytaseenzyme codierende nukleinsäuren, diese enthaltende vektoren und wirtszellen und verfahren zur herstellung und verwendung davon | |
| ATE258189T1 (de) | Verfahren zur herstellung von erythropoietin frei von tierischen proteinen | |
| ATE380878T1 (de) | Verfahren und zusammensetzungen für die proteinexpression und reinigung | |
| DE60125218D1 (de) | Verfahren zur herstellung von humanem serumalbumin unter verwendung eines aufwarmschrittes | |
| ATE517185T1 (de) | Methoden zur herstellung von pflanzen mit erhöhtem ölsäuregehalt | |
| SG149000A1 (en) | Gag binding proteins | |
| DE60036636D1 (de) | Rinder-kollagen und verfahren zur herstelling rekombinantes gelatin | |
| ATE365203T1 (de) | Hefe-extraktlösung, ihre herstellung und verwendung zur zellfreien proteinsynthese | |
| ATE309353T1 (de) | Verfahren zur herstellung von rekombinanten peptiden | |
| DE60027932D1 (de) | Verfahren zur herstellung von proteinhydrolysaten | |
| ATE387497T1 (de) | Samenspezifische 7s-alpha-promoter zur expression von genen in pflanzen | |
| DE60126148D1 (de) | Verfahren zur herstellung von heterologen proteinen in fungi | |
| ATE232904T1 (de) | Verfahren zur herstellung proteinöser substanzen | |
| ATE550437T1 (de) | Verfahren zur expression und reinigung von immunotoxinen | |
| ATE499845T1 (de) | Weisses proteinklebermehl und verfahren für seine verwendung | |
| DE50301559D1 (de) | Verfahren zur herstellung von tocotrienol-angereicherten präparationen | |
| DE69630524D1 (de) | Methoden zur aufreinigung von authentischem igf aus hefewirtszellen | |
| ATE532793T1 (de) | Verfahren zur herstellung von molekülen mit verminderter immunogenität | |
| ATE400662T1 (de) | Herstellung von frostschutzprotein | |
| ATE299944T1 (de) | System zur herstellung von proteinen | |
| ATE538209T1 (de) | L-threonin herstellendes bakterium und verfahren zur herstellung von l-threonin | |
| ATE319837T1 (de) | Verfahren zur herstellung von rekombinantem trypsin | |
| DE60318882D1 (de) | Uroplakin-ii-promotor aus schwein und verfahren zur herstellung nützlicher proteine unter verwendung des promotors | |
| DE60011785D1 (de) | Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1539966 Country of ref document: EP |